Literature DB >> 28778242

Pharmacologic Management of Excessive Daytime Sleepiness.

Shinichi Takenoshita1, Seiji Nishino2.   

Abstract

Excessive daytime sleepiness (EDS) is related to medical and social problems, including mental disorders, physical diseases, poor quality of life, and so forth. According to the International Classification of Sleep Disorders, Third Edition, diseases that result from EDS are narcolepsy type 1, narcolepsy type 2, idiopathic hypersomnia, hypersomnia due to a medical disorder, and others. EDS is usually treated using amphetamine-like central nervous system stimulants or modafinil and its R-enantiomer, armodafinil, wake-promoting compounds unrelated to amphetamines; a variety of new drugs are under development. The side effects of some stimulants are potent and careful selection and management are required.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Excessive daytime sleepiness; Idiopathic hypersomnia; Narcolepsy; Stimulants

Mesh:

Substances:

Year:  2017        PMID: 28778242     DOI: 10.1016/j.jsmc.2017.03.019

Source DB:  PubMed          Journal:  Sleep Med Clin        ISSN: 1556-407X


  7 in total

1.  Effects of Pharmacotherapy Treatment on Patient-Reported Outcomes in a Narcolepsy and Idiopathic Hypersomnia Cohort.

Authors:  Maeve Pascoe; James Bena; Nancy Foldvary-Schaefer
Journal:  J Clin Sleep Med       Date:  2019-10-30       Impact factor: 4.062

2.  Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea.

Authors:  Sarah Ronnebaum; Morgan Bron; Dipen Patel; Diane Menno; Shay Bujanover; David Kratochvil; Eleanor Lucas; Carl Stepnowsky
Journal:  J Clin Sleep Med       Date:  2021-12-01       Impact factor: 4.062

Review 3.  Excessive Daytime Sleepiness in Parkinson's Disease: Clinical Implications and Management.

Authors:  Yun Shen; Jun-Ying Huang; Jie Li; Chun-Feng Liu
Journal:  Chin Med J (Engl)       Date:  2018-04-20       Impact factor: 2.628

4.  A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor.

Authors:  Lawrence P Carter; Jack E Henningfield; Y Grace Wang; Yuan Lu; Debra Kelsh; Bradley Vince; Edward Sellers
Journal:  J Psychopharmacol       Date:  2018-10-01       Impact factor: 4.153

5.  Management Of Excessive Sleepiness In Patients With Narcolepsy And OSA: Current Challenges And Future Prospects.

Authors:  Ashima S Sahni; Melissa Carlucci; Malik Malik; Bharati Prasad
Journal:  Nat Sci Sleep       Date:  2019-10-23

6.  Case report: narcolepsy type 2 due to temporal lobe glioma.

Authors:  Yuangao Liao; Yan He; You Yang; Xiaojie Li; Fengzhen Huang
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

Review 7.  Approaches to the Pharmacological Management of Jet Lag.

Authors:  Josephine Arendt
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.